310 related articles for article (PubMed ID: 27748152)
1. Developments with investigational Janus kinase inhibitors for rheumatoid arthritis.
Semerano L; Decker P; Clavel G; Boissier MC
Expert Opin Investig Drugs; 2016 Dec; 25(12):1355-1359. PubMed ID: 27748152
[No Abstract] [Full Text] [Related]
2. Selective JAK inhibitors in development for rheumatoid arthritis.
Norman P
Expert Opin Investig Drugs; 2014 Aug; 23(8):1067-77. PubMed ID: 24818516
[TBL] [Abstract][Full Text] [Related]
3. Peficitinib: First Global Approval.
Markham A; Keam SJ
Drugs; 2019 Jun; 79(8):887-891. PubMed ID: 31093950
[TBL] [Abstract][Full Text] [Related]
4. Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis.
Nakayamada S; Kubo S; Iwata S; Tanaka Y
BioDrugs; 2016 Oct; 30(5):407-419. PubMed ID: 27577235
[TBL] [Abstract][Full Text] [Related]
5. Janus kinase inhibitors for rheumatoid arthritis.
Yamaoka K
Curr Opin Chem Biol; 2016 Jun; 32():29-33. PubMed ID: 26994322
[TBL] [Abstract][Full Text] [Related]
6. Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib.
Yamaoka K; Tanaka Y
Expert Opin Pharmacother; 2014 Jan; 15(1):103-13. PubMed ID: 24188100
[TBL] [Abstract][Full Text] [Related]
7. Kinase inhibitors: the next generation of therapies in the treatment of rheumatoid arthritis.
MacFarlane LA; Todd DJ
Int J Rheum Dis; 2014 May; 17(4):359-68. PubMed ID: 24460872
[TBL] [Abstract][Full Text] [Related]
8. Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis.
Iwata S; Tanaka Y
Expert Rev Clin Immunol; 2016 Oct; 12(10):1047-57. PubMed ID: 27253519
[TBL] [Abstract][Full Text] [Related]
9. Critical Assessment of Pharmacokinetic Drug-Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment.
Veeravalli V; Dash RP; Thomas JA; Babu RJ; Madgula LMV; Srinivas NR
Drug Saf; 2020 Aug; 43(8):711-725. PubMed ID: 32367507
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of peficitinib in rheumatoid arthritis.
Kaneko Y
Mod Rheumatol; 2020 Sep; 30(5):773-778. PubMed ID: 32643492
[TBL] [Abstract][Full Text] [Related]
11. Malignancy and Janus Kinase Inhibition.
Sivaraman P; Cohen SB
Rheum Dis Clin North Am; 2017 Feb; 43(1):79-93. PubMed ID: 27890175
[TBL] [Abstract][Full Text] [Related]
12. Promising new treatments for rheumatoid arthritis - the kinase inhibitors.
Yazici Y; Regens AL
Bull NYU Hosp Jt Dis; 2011; 69(3):233-7. PubMed ID: 22035435
[TBL] [Abstract][Full Text] [Related]
13. [A new therapeutical option for chronic inflammation in rheumatology: janus kinases inhibitors (JAK)].
Varisco PA; So A
Rev Med Suisse; 2014 Jan; 10(414):187-91. PubMed ID: 24624736
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review.
Jegatheeswaran J; Turk M; Pope JE
Immunotherapy; 2019 Jun; 11(8):737-754. PubMed ID: 30955397
[TBL] [Abstract][Full Text] [Related]
15. [Relevance of involvement of tofacitinib in T cell subsets to clinical courses and adverse events in patients with rheumatoid arthritis].
Sonomoto K; Tanaka Y
Nihon Rinsho Meneki Gakkai Kaishi; 2015; 38(6):443-7. PubMed ID: 27118331
[TBL] [Abstract][Full Text] [Related]
16. Small molecular compounds in development for rheumatoid arthritis.
van Vollenhoven RF
Curr Opin Rheumatol; 2013 May; 25(3):391-7. PubMed ID: 23492738
[TBL] [Abstract][Full Text] [Related]
17. Baricitinib (olumiant) for rheumatoid arthritis.
Med Lett Drugs Ther; 2018 Jul; 60(1551):120-121. PubMed ID: 30036348
[No Abstract] [Full Text] [Related]
18. Baricitinib: JAK inhibition for rheumatoid arthritis.
Gras J
Drugs Today (Barc); 2016 Oct; 52(10):543-550. PubMed ID: 27910962
[TBL] [Abstract][Full Text] [Related]
19. Filgotinib for the treatment of rheumatoid arthritis.
Taylor PC; Abdul Azeez M; Kiriakidis S
Expert Opin Investig Drugs; 2017 Oct; 26(10):1181-1187. PubMed ID: 28838249
[TBL] [Abstract][Full Text] [Related]
20. The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib.
Choy EHS; Miceli-Richard C; González-Gay MA; Sinigaglia L; Schlichting DE; Meszaros G; de la Torre I; Schulze-Koops H
Clin Exp Rheumatol; 2019; 37(4):694-704. PubMed ID: 30767864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
